| Year |
Citation |
Score |
| 2020 |
Sriuranpong V, Luangdilok S, Chantranuwatana P, Leeladejkul N, Pornpatanarak N, Benjacholamas V, Sitthideatphaiboon P, Vinayanuwattikun C, Pisitkun T. MCM4 as a prognostic biomarker of early-stage lung cancer. Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.15_Suppl.E21033 |
0.333 |
|
| 2019 |
Qin S, Chan SL, Sukeepaisarnjaroen W, Han G, Choo SP, Sriuranpong V, Pan H, Yau T, Guo Y, Chen M, Ren Z, Xu J, Yen CJ, Lin ZZ, Manenti L, et al. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology. 11: 1758835919889001. PMID 31853265 DOI: 10.1177/1758835919889001 |
0.305 |
|
| 2019 |
Thongprasert S, Geater SL, Clement D, Abdelaziz A, Reyes-Igama J, Jovanovic D, Alexandru A, Schenker M, Sriuranpong V, Serwatowski P, Suresh S, Cseh A, Gaafar R. Afatinib in locally advanced/metastatic NSCLC harboring common mutations, after chemotherapy: a Phase IV study. Lung Cancer Management. 8: LMT15. PMID 31807143 DOI: 10.2217/Lmt-2019-0004 |
0.386 |
|
| 2019 |
Vimolchalao V, Sakdejayont S, Wongchanapai P, Sukprakun S, Angspatt P, Thawinwisan W, Chenaksara P, Sriuranpong V, Vinayanuwatikun C, Parinyanitikun N, Poovorawan N, Tanasanvimon S. The efficacy and safety of the addition of olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. International Journal of Clinical Oncology. PMID 31776732 DOI: 10.1007/S10147-019-01570-3 |
0.302 |
|
| 2019 |
Sitthideatphaiboon P, Santisukwongchote S, Khunsri S, Sathitruangsak C, Chantranuwat P, Vinayanuwattikun C, Sriuranpong V. Paradoxical prognostic phenomenon of plasma T-cell-derived circulating DNA level in advanced non-small cell lung cancer. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 22: 1117-1125. PMID 31754936 DOI: 10.1007/S12094-019-02238-0 |
0.362 |
|
| 2019 |
Gray JE, Okamoto I, Sriuranpong V, Vansteenkiste JF, Imamura F, Lee JS, Pang YK, Cobo M, Kasahara K, Cheng Y, Nogami N, Cho EK, Su WC, Zhang G, Huang X, et al. Tissue and Plasma Mutation Analysis in the FLAURA Trial: Osimertinib vs Comparator EGFR-TKI as First-Line Treatment in Patients with Mutated Advanced NSCLC. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31439584 DOI: 10.1158/1078-0432.Ccr-19-1126 |
0.343 |
|
| 2019 |
Tiankanon K, Kongkam P, Luangsukrerk T, Sriuranpong V, Nantavithya C, Jantarattana T, Canones A, Angsuwatcharakon P, Ridtitid W, Kullavanijaya P, Rerknimitr R. IDDF2019-ABS-0171 EUS-Guided radiofrequency ablation as adjunctive treatment for unresectable pancreatic cancer versus chemotherapy alone (ERAP) Gut. 68. DOI: 10.1136/Gutjnl-2019-Iddfabstracts.179 |
0.319 |
|
| 2019 |
Kongkam P, Tiankanon K, Cañones AR, Luangsukrerk T, Seo DW, Nantavithya C, Jantarattana T, Sriuranpong V, Angsuwatcharakon P, Ridtitid W, Kullavanijaya P, Rerknimitr R. 385 Eus-Guided Radiofrequency Ablation Plus Chemotherapy Versus Chemotherapy Alone For Unresectable Pancreatic Cancer (Erap): Preliminary Results Of A Prospective Comparative Study Gastrointestinal Endoscopy. 89. DOI: 10.1016/J.Gie.2019.04.056 |
0.333 |
|
| 2018 |
Lin CC, Taylor M, Boni V, Brunsvig PF, Geater SL, Salvagni S, Garrido Lopez P, Özgüroğlu M, Sriuranpong V, Ponce Aix S, Ascierto PA, Fasolo A, Sezer A, Kowalski DM, Faris JE, et al. Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii413. PMID 32137036 DOI: 10.1093/Annonc/Mdy288.032 |
0.357 |
|
| 2018 |
Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discovery. PMID 29848605 DOI: 10.1158/2159-8290.Cd-18-0229 |
0.335 |
|
| 2018 |
Tanasanvimon S, Ungtrakul T, Poovorawan N, Parinyanitikul N, Vinayanuwattikun C, Mingmalairak S, Luangdilok S, Lamlertthon W, Sriuranpong V. A phase 2 study of s-1 plus leucovorin in patients with untreated advanced cholangiocarcinoma (CCA). Journal of Clinical Oncology. 36: 467-467. DOI: 10.1200/Jco.2018.36.4_Suppl.467 |
0.303 |
|
| 2018 |
Sriuranpong V, Altundag O, Clingan P, Rizvi N, Frontera OA, Sezer A, Paydas S, Shavdia M, Bondarenko I, Gladkov O, Lee S, Li S, Snodgrass P, Rietschel P. 108TiPEMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 ≥50% Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy487.039 |
0.337 |
|
| 2018 |
Thongprasert S, Geater SL, Clement D, Abdelaziz A, Reyes-Igama J, Jovanovic D, Alexandru A, Schenker M, Sriuranpong V, Serwatowski P, Suresh S, Cseh A, Gaafar R. Afatinib in chemotherapy pre-treated EGFR mutation-positive NSCLC. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy446.008 |
0.301 |
|
| 2017 |
Chayangsu C, Khunsri S, Sriuranpong V, Tanasanvimon S. The correlations between serum amphiregulin and other clinicopathological factors in colorectal cancer. Journal of Gastrointestinal Oncology. 8: 980-984. PMID 29299357 DOI: 10.21037/Jgo.2017.08.15 |
0.326 |
|
| 2017 |
Lertbutsayanukul C, Tharavej C, Klaikeaw N, Prayongrat A, Lowanitchai C, Sriuranpong V. High dose radiation with chemotherapy followed by salvage esophagectomy among patients with locally advanced esophageal squamous cell carcinoma. Thoracic Cancer. PMID 28322515 DOI: 10.1111/1759-7714.12427 |
0.318 |
|
| 2017 |
Tanpipattanakul W, Poovorawan N, Rattananupong T, Laoitthi P, Sithidetphaiboon P, Thanasanvimon S, Sriuranpong V, Parinyanitikul N. Feasibility of withholding dexamethasone premedication for hypersensitivity reactions associated with paclitaxel administration Asian Biomedicine. 10: 371-377. DOI: 10.5372/1905-7415.1004.500 |
0.329 |
|
| 2017 |
Uttamapinan S, Iampenkhae K, Rattananupong T, Poovorawan N, Sriuranpong V, Parinyanitikul N. A clinicopathological prediction model for recurrence in patients with early-stage hormone-receptor-positive, HER2-negative breast cancer at King Chulalongkorn Memorial Hospital. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E12015 |
0.313 |
|
| 2017 |
Sakdejayont S, Chantranuwat P, Poovorawan N, Sitthideatphaiboon P, Parinyanitikul N, Vinayanuwattikun C, Tanasanvimon S, Sriuranpong V. Comparing programmed death ligand-1 expression on tumor cells before and after acquiring resistance to tyrosine kinase inhibitor in EGFR harbouring non-small cell lung cancer. Journal of Clinical Oncology. 35: 11617-11617. DOI: 10.1200/Jco.2017.35.15_Suppl.11617 |
0.375 |
|
| 2017 |
Sriuranpong V, Kim TW, Shen L, Xu J, Pan H, Xu R, Han S, Liu T, Park YS, Shi C, Bai Y, Bi F, Ahn JB, Qin S, Li Q, et al. Phase III study of trifluridine/tipiracil versus placebo in Asian patients with metastatic colorectal cancer (TERRA study): Country subgroup Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx659 |
0.329 |
|
| 2017 |
Reungwetwattana T, Laohavinij S, Lamlertthon W, Chewaskulyong B, Dechaphunkul A, Detarkom S, Muntham D, Poovorawan N, Srimuninnimit V, Sriuranpong V. P3.01-042 Efficacy & Tolerability of Afatinib in NSCLC Patients Prior Exposure to 1st Generation EGFR TKI: Thailand Multicenter Study Journal of Thoracic Oncology. 12. DOI: 10.1016/J.Jtho.2017.09.1483 |
0.32 |
|
| 2016 |
Kaewbubpa W, Areepium N, Sriuranpong V. Effect of the ERCC1 (C118T) Polymorphism on Treatment Response in Advanced Non-Small Cell Lung Cancer Patients Undergoing Platinum-Based Chemotherapy Asian Pacific Journal of Cancer Prevention : Apjcp. 17: 4917-4920. PMID 28032496 DOI: 10.22034/Apjcp.2016.17.11.4917 |
0.323 |
|
| 2016 |
Mok T, Ladrera G, Srimuninnimit V, Sriuranpong V, Yu CJ, Thongprasert S, Sandoval-Tan J, Lee JS, Fuerte F, Shames DS, Klughammer B, Truman M, Perez-Moreno P, Wu YL. Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 98: 1-8. PMID 27393499 DOI: 10.1016/J.Lungcan.2016.04.023 |
0.304 |
|
| 2016 |
Yao JC, Oh D, Qian J, Park YS, Fabian H, Antonia R, Ito T, Jia L, Komoto I, Sriuranpong V, Shimada Y. ISY-12-4Efficacy and Safety of Everolimus in Advanced Nonfunctional Neuroendocrine Tumors (NET) of Lung or Gastrointestinal (GI) Origin: Findings From the Asian Subgroup Analysis of the RADIANT-4 Study Annals of Oncology. 27. DOI: 10.1093/Annonc/Mdw463.003 |
0.341 |
|
| 2015 |
Park K, Yu CJ, Kim SW, Lin MC, Sriuranpong V, Tsai CM, Lee JS, Kang JH, Chan KC, Perez-Moreno P, Button P, Ahn MJ, Mok T. First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study. Jama Oncology. 1-8. PMID 26720423 DOI: 10.1001/Jamaoncol.2015.4921 |
0.409 |
|
| 2015 |
Neesanun S, Sriuranpong V. Association of plasma CXCL12 level and bone metastasis in advance stage non-small cell lung cancer patients in King Chulalongkorn Memorial Hospital. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E19099 |
0.336 |
|
| 2015 |
Thongprasert S, Alexandru A, Schenker M, Abdelaziz A, Clement D, Boldeanu C, Jovanovic D, Reyes-Igama J, Petrović M, Geater S, Radosavljevic D, Perin B, Krzakowski M, Serwatowski P, Parra J, ... Sriuranpong V, et al. 477TiPPhase IV study of afatinib as second-line therapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring common epidermal growth factor receptor (EGFR) mutations (Del19 and/or L858R) Annals of Oncology. 26. DOI: 10.1093/Annonc/Mdv532.61 |
0.385 |
|
| 2014 |
Cheng AL, Li J, Vaid AK, Ma BB, Teh C, Ahn JB, Bello M, Charoentum C, Chen LT, de Lima Lopes G, Ho GF, Kong HL, Lam KO, Liu TS, Park YS, ... Sriuranpong V, et al. Adaptation of international guidelines for metastatic colorectal cancer: an asian consensus. Clinical Colorectal Cancer. 13: 145-55. PMID 25209093 DOI: 10.1016/J.Clcc.2014.06.004 |
0.307 |
|
| 2014 |
Srimuninnimit V, Sriuranpong V, Suwanvecho S. Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study. Asia-Pacific Journal of Clinical Oncology. 10: 255-60. PMID 24810940 DOI: 10.1111/Ajco.12191 |
0.307 |
|
| 2014 |
Lee SH, Bang YJ, Mainwaring P, Ng C, Chang JW, Kwong P, Li RK, Sriuranpong V, Toh CK, Yuan J, Pitman Lowenthal S, Chung HC. Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy. Asia-Pacific Journal of Clinical Oncology. 10: 237-45. PMID 24576311 DOI: 10.1111/Ajco.12163 |
0.313 |
|
| 2014 |
Poovorawan N, Chantranuwat P, Keelawat S, Sitthideatphaiboon P, Parinyanitikul N, Vinayanuwattikun C, Tanasanvimon S, Sriuranpong V. Analysis of KRT14 and SFTPB expression by immunohistochemistry method in squamous cell carcinoma of lung and head-neck cancer tissue. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E22127 |
0.362 |
|
| 2014 |
Sitthideatphaiboon P, Teerapakpinyo C, Klaikaew N, Tanasanvimon S, Vinayanuwattikun C, Parinyanitikul N, Poovorawan N, Sriuranpong V. Prevalence of KRAS gene mutation in ampullary cancer in Thai patients. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E15175 |
0.355 |
|
| 2014 |
Chayangsu C, Kanjanasilp P, Malakorn S, Sahakitrungruang C, Tanasanvimon S, Sitthideatphaiboon P, Sriuranpong V. P0227 Utility of pre-treatment serum amphiregulin in colorectal carcinoma European Journal of Cancer. 50. DOI: 10.1016/J.Ejca.2014.03.271 |
0.329 |
|
| 2014 |
Neesanun S, Sriuranpong V. P0151 Association of plasma CXCL12 and bone metastasis in advanced stage non-small-cell lung cancer European Journal of Cancer. 50. DOI: 10.1016/J.Ejca.2014.03.195 |
0.304 |
|
| 2013 |
D'Cruz A, Lin T, Anand AK, Atmakusuma D, Calaguas MJ, Chitapanarux I, Cho BC, Goh BC, Guo Y, Hsieh WS, Hu C, Kwong D, Lin JC, Lou PJ, Lu T, ... ... Sriuranpong V, et al. Consensus recommendations for management of head and neck cancer in Asian countries: A review of international guidelines Oral Oncology. 49: 872-877. PMID 23830839 DOI: 10.1016/J.Oraloncology.2013.05.010 |
0.313 |
|
| 2013 |
Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen YM, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. The Lancet. Oncology. 14: 777-86. PMID 23782814 DOI: 10.1016/S1470-2045(13)70254-7 |
0.399 |
|
| 2013 |
Chunhacha P, Sriuranpong V, Chanvorachote P. Epithelial-mesenchymal transition mediates anoikis resistance and enhances invasion in pleural effusion-derived human lung cancer cells. Oncology Letters. 5: 1043-1047. PMID 23426647 DOI: 10.3892/Ol.2013.1108 |
0.377 |
|
| 2013 |
Lertbutsayanukul C, Chiewaratanapong P, Klaikeaw N, Tepmongkol S, Piyavisetpat N, Sriuranpong V, Tharavej C. Phase I study of integrating PET/CT and dose-escalated intensity modulated radiation therapy using a simultaneous integrated boost technique for thoracic esophageal cancer Asian Biomedicine. 7: 657-667. DOI: 10.5372/1905-7415.0705.224 |
0.314 |
|
| 2013 |
Gradishar WJ, Bachelot TD, Saletan S, Graham AM, Liedke PER, Azevedo SJ, Sriuranpong V, Cardoso F. BOLERO-4: Multicenter, open-label, phase II study of everolimus plus letrozole as first-line therapy in ER+, HER2- metastatic breast cancer. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps661 |
0.32 |
|
| 2013 |
Mok T, Wu YL, Lee JS, Yu C, Sriuranpong V, Wen W, Tsai J, Truman M, Klughammer B, Wu L. Detection of EGFR-activating mutations from plasma DNA as a potent predictor of survival outcomes in FASTACT 2: A randomized phase III study on intercalated combination of erlotinib (E) and chemotherapy (C). Journal of Clinical Oncology. 31: 8021-8021. DOI: 10.1200/Jco.2013.31.15_Suppl.8021 |
0.324 |
|
| 2013 |
Azevedo S, Bachelo T, Gradishar W, Ringeisen F, Brechenmacher T, Liedke PER, Cardoso F, Sriuranpong V. Po58 Efficacy And Safety Of First-Line Everolimus Plus Letrozole In Er+ Her2− Metastatic Breast Cancer: A Multi-Center, Open-Label, Phase 2 Trial Bolero-4 The Breast. 22. DOI: 10.1016/S0960-9776(13)70072-9 |
0.302 |
|
| 2012 |
Chanvorachote P, Luanpitpong S, Chunhacha P, Promden W, Sriuranpong V. Expression of CA125 and cisplatin susceptibility of pleural effusion-derived human lung cancer cells from a Thai patient. Oncology Letters. 4: 252-256. PMID 22844364 DOI: 10.3892/Ol.2012.711 |
0.408 |
|
| 2012 |
Park K, Tsai C, Ahn M, Yu C, Kim S, Sriuranpong V, Kuo HP, Lee J, Kang JH, Lin M, Geater SL, Chang G, Seetalarom K, So PFP, Lai R, et al. ASPIRATION: Phase II study of continued erlotinib beyond RECIST progression in Asian patients (pts) with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.Tps7614 |
0.356 |
|
| 2012 |
Yalcin S, Buyukberber S, Yilmaz U, Lee P, Srimuninnimit V, Lin P, Elserafy MM, Manieh M, Sunpaweravong P, Istomin Y, Sriuranpong V, Hwang T. Phase II study of adjuvant imatinib mesylate (IM) in patients after resection of primary gastrointestinal stromal tumor (GIST): Efficacy and safety at one year. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E20514 |
0.319 |
|
| 2012 |
Mok T, Wu YL, Thongprasert S, Yu C, Zhang L, Ladrera GE, Srimuninnimit V, Sriuranpong V, Sandoval-Tan J, Zhu Y, Liao M, Zhou C, Pan H, Lee V, Chen Y, et al. A randomized placebo-controlled phase III study of intercalated erlotinib with gemcitabine/platinum in first-line advanced non-small cell lung cancer (NSCLC): FASTACT-II. Journal of Clinical Oncology. 30: 7519-7519. DOI: 10.1200/Jco.2012.30.15_Suppl.7519 |
0.37 |
|
| 2011 |
Mok TS, Hsia TC, Tsai CM, Tsang K, Chang GC, Chang JW, Sirisinha T, Thitiya S, Sriuranpong V, Thongprasert S, Chua DT, Moore N, Manegold C. Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: a substudy of the Avastin in Lung trial. Asia-Pacific Journal of Clinical Oncology. 7: 4-12. PMID 21585703 DOI: 10.1111/J.1743-7563.2011.01397.X |
0.414 |
|
| 2009 |
Mok TS, Wu YL, Yu CJ, Zhou C, Chen YM, Zhang L, Ignacio J, Liao M, Srimuninnimit V, Boyer MJ, Chua-Tan M, Sriuranpong V, Sudoyo AW, Jin K, Johnston M, et al. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5080-7. PMID 19738125 DOI: 10.1200/Jco.2008.21.5541 |
0.4 |
|
| 2008 |
Yanatatsaneejit P, Chalermchai T, Kerekhanjanarong V, Shotelersuk K, Supiyaphun P, Mutirangura A, Sriuranpong V. Promoter hypermethylation of CCNA1, RARRES1, and HRASLS3 in nasopharyngeal carcinoma. Oral Oncology. 44: 400-6. PMID 17689134 DOI: 10.1016/J.Oraloncology.2007.05.008 |
0.316 |
|
| 2007 |
Kupferman ME, Patel V, Sriuranpong V, Amornphimoltham P, Jasser SA, Mandal M, Zhou G, Wang J, Coombes K, Multani A, Pathak S, Silvio Gutkind J, Myers JN. Molecular analysis of anoikis resistance in oral cavity squamous cell carcinoma. Oral Oncology. 43: 440-54. PMID 16978912 DOI: 10.1016/J.Oraloncology.2006.04.016 |
0.351 |
|
| 2006 |
Squarize CH, Castilho RM, Sriuranpong V, Pinto DS, Gutkind JS. Molecular cross-talk between the NFkappaB and STAT3 signaling pathways in head and neck squamous cell carcinoma. Neoplasia (New York, N.Y.). 8: 733-46. PMID 16984731 DOI: 10.1593/Neo.06274 |
0.329 |
|
| 2005 |
Sriuranpong V, Chantranuwat C, Huapai N, Chalermchai T, Leungtaweeboon K, Lertsanguansinchai P, Voravud N, Mutirangura A. High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand. Cancer Letters. 239: 292-7. PMID 16243431 DOI: 10.1016/J.Canlet.2005.08.029 |
0.302 |
|
| 2005 |
Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, Jin N, Collins BJ, Nelkin BD, Chen H, Ball DW. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. The Journal of Clinical Endocrinology and Metabolism. 90: 4350-6. PMID 15870121 DOI: 10.1210/Jc.2005-0540 |
0.562 |
|
| 2004 |
Sriuranpong V, Mutirangura A, Gillespie JW, Patel V, Amornphimoltham P, Molinolo AA, Kerekhanjanarong V, Supanakorn S, Supiyaphun P, Rangdaeng S, Voravud N, Gutkind JS. Global gene expression profile of nasopharyngeal carcinoma by laser capture microdissection and complementary DNA microarrays. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4944-58. PMID 15297395 DOI: 10.1158/1078-0432.Ccr-03-0757 |
0.344 |
|
| 2004 |
Amornphimoltham P, Sriuranpong V, Patel V, Benavides F, Conti CJ, Sauk J, Sausville EA, Molinolo AA, Gutkind JS. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 4029-37. PMID 15217935 DOI: 10.1158/1078-0432.Ccr-03-0249 |
0.373 |
|
| 2003 |
Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, Sriuranpong V, Iso T, Meszoely IM, Wolfe MS, Hruban RH, Ball DW, Schmid RM, Leach SD. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell. 3: 565-76. PMID 12842085 DOI: 10.1016/S1535-6108(03)00140-5 |
0.345 |
|
| 2002 |
Sriuranpong V, Borges MW, Strock CL, Nakakura EK, Watkins DN, Blaumueller CM, Nelkin BD, Ball DW. Notch signaling induces rapid degradation of achaete-scute homolog 1. Molecular and Cellular Biology. 22: 3129-39. PMID 11940670 DOI: 10.1128/Mcb.22.9.3129-3139.2002 |
0.594 |
|
| 2001 |
Nakakura EK, Watkins DN, Sriuranpong V, Borges MW, Nelkin BD, Ball DW. Mammalian Scratch participates in neuronal differentiation in P19 embryonal carcinoma cells. Brain Research. Molecular Brain Research. 95: 162-6. PMID 11687288 DOI: 10.1016/S0169-328X(01)00246-7 |
0.579 |
|
| 2001 |
Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, Ball DW. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Research. 61: 3200-5. PMID 11306509 |
0.478 |
|
| 2001 |
Nakakura EK, Watkins DN, Schuebel KE, Sriuranpong V, Borges MW, Nelkin BD, Ball DW. Mammalian Scratch: a neural-specific Snail family transcriptional repressor. Proceedings of the National Academy of Sciences of the United States of America. 98: 4010-5. PMID 11274425 DOI: 10.1073/Pnas.051014098 |
0.589 |
|
| 2001 |
Nakakura EK, Sriuranpong V, Borges MW, Watkins N, Nelkin BD, Ball DW, Chen H. Regulation of the neuroendocrine phenotype in pancreatic carcinoid tumor cells Gastroenterology. 120: A349. DOI: 10.1016/S0016-5085(08)81734-9 |
0.612 |
|
| 1998 |
Pawarode A, Voravud N, Sriuranpong V, Kullavanijaya P, Patt YZ. Natural history of untreated primary hepatocellular carcinoma: A retrospective study of 157 patients American Journal of Clinical Oncology. 21: 386-391. PMID 9708639 DOI: 10.1097/00000421-199808000-00014 |
0.339 |
|
| Show low-probability matches. |